What's Happening?
Allergan Aesthetics, an AbbVie company, has released results from two Phase 4 studies, HARMONY IN DIVERSITY and HALO, evaluating aesthetic treatments in adults using GLP-1 medications. The HARMONY IN DIVERSITY study, the first to combine neurotoxin and hyaluronic
acid (HA) injectables in this population, showed statistically significant improvements in satisfaction with facial appearance, skin quality, and psychological and social function among participants. These improvements were observed following a regimen that included HA injectables, onabotulinumtoxinA, and a specified skincare routine. Interim results from the HALO study, which focused on HA injectables, also indicated high patient satisfaction, with 95.7% of participants reporting they still looked like themselves and 82.6% satisfied with their natural appearance. These findings were presented at the 2026 American Society for Dermatologic Surgery (ASDS) Annual Meeting.
Why It's Important?
The findings are significant because individuals undergoing weight loss with GLP-1 medications often experience facial changes, such as volume loss and altered skin quality, which can impact their self-image and social interactions. This research provides crucial data for healthcare providers to develop informed treatment plans and manage patient expectations in this specific demographic. The studies highlight the potential of combined aesthetic treatments to address these concerns, offering solutions that enhance patient satisfaction with their facial appearance and overall well-being. The data supports the use of Allergan Aesthetics' portfolio in a multimodal approach, demonstrating its relevance in a growing patient population utilizing GLP-1 medications for weight management. This could lead to increased demand for aesthetic procedures tailored to the needs of GLP-1 users, influencing the medical aesthetics market.
What's Next?
Allergan Aesthetics plans to continue its scientific program, advancing research across medical weight loss, multimodal treatment, neurotoxin innovation, and skin quality. The company's ongoing research aims to generate further evidence to help providers make informed decisions about combining products in practice. Future studies may explore long-term outcomes, optimal treatment protocols, and the psychological benefits of aesthetic interventions for GLP-1 medication users. The insights gained from these studies are expected to influence clinical guidelines and product development within the aesthetic medicine industry, potentially leading to new treatment options and expanded indications for existing products. The focus on patient-reported outcomes, such as satisfaction with facial appearance and psychological function, will likely remain central to future research endeavors.
Beyond the Headlines
The rise of GLP-1 medications for weight loss has created a new demographic with unique aesthetic needs, prompting the medical aesthetics industry to adapt. This development underscores a broader trend where advancements in one medical field can create ripple effects in others. The emphasis on maintaining a 'natural look' and preserving self-identity, as highlighted by the HALO study, reflects evolving patient preferences in aesthetic treatments. It suggests a shift towards interventions that enhance rather than drastically alter appearance, particularly for those undergoing significant body changes. This also raises ethical considerations regarding body image and the psychological impact of rapid weight loss, positioning aesthetic treatments not just as cosmetic enhancements but as tools for psychological and social adjustment.
